Actavis aims to copy Depomed's Gralise drug; Roche agrees to settle Raptiva claims, lawyer says;

@FiercePharma: Litigation, recalls haunt J&J's Q4 earnings, and 2012 forecasts fall short of analyst estimates--Bloomberg. Report | Follow @FiercePharma

> Depomed said the generics maker Actavis has asked the FDA to approve a knockoff version of Gralise, which is one of its two approved products. Article

> Roche ($RHHBY) has agreed to settle a lawsuit over its now-withdrawn psoriasis drug Raptiva for an undisclosed amount, a plaintiffs' lawyer said. Story

> West Virginia lawmakers are proposing to make pseudoephedrine-containing cold remedies available only by prescription, and drugmakers are fighting back. News

> If Ireland changes its reference pricing system to key off of the lowest drug prices in other EU countries rather than average prices, it could save up to 25%, a government report found. Report

> The FDA's Center for Devices and Radiological Health set personalized medicine as one of its priorities for the current year, aiming for draft guidance on co-development of drugs and diagnostics by year's end. More

> Boehringer Ingelheim tapped Paul Fonteyne to serve as president and CEO of its U.S. operatings; he'll take over from J. Martin Carroll, who's focusing on corporate strategy and development. Release

> India's Lupin expects higher taxes to soften earnings growth, but demand for its generics drugs is anticipated to remain strong, boosting sales. More

> The federal government in Pakistan arrested the top executives of three pharmaceutical companies that produced heart drugs linked to the deaths of roughly 63 patients. Article

Biotech News

@FierceBiotech: Is Vertex as far behind in the oral hep C race as one might think? Maybe not. More | Follow @FierceBiotech

@JohnCFierce: Novo's new research center in Seattle will combine basic research/FIH studies for Type 1 diabetes. About 20 staffers. Release | Follow @JohnCFierce

@RyanMFierce: Ipsen has handed back rights to a Parkinson's drug to Santhera ($SANN), as Ipsen changes focus to late-stage contenders. Story | Follow @RyanMFierce

@MarkHFierce: B.U. has found some genetic triggers behind the onset of menopause. Info could help treat age-related diseases. Release | Follow @MarkHFierce

> Novo crafts fast-track R&D model for new diabetes drug unit. More

> Scientists believe "magic" mushrooms could effectively treat depression. Story

Pharma Manufacturing News

> Pakistan suspects heart drug contamination in patient deaths, seals plant. News

> Law firm brings logistics savvy to Miami. Article

> Roche workers protest use of contractors. News

> Pfizer revels in massive Prevnar vax job. Interview

> Balance adaptability, planning in supply chain, Tompkins advises. Item

> GSK's CEO Witty wants U.K. focus on manufacturing. More

Research News

> Obama seeks to beat Alzheimer's by 2025. Article

> Eat your vegetables to fight colon cancer, plus 2 other discoveries. More

> Genetic analysis yields hypertension clue. Story

> U.K. team finds gene link for esophageal cancer. News

> Targeting NKp46 boosts immune response, Innate Pharma believes. Item

And Finally... Studies of patients on magic mushrooms could point the way to new depression drugs, scientists say. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.